OptiNose, Inc. (NASDAQ:OPTN) CEO Sells $33,729.04 in Stock

OptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud sold 6,376 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OptiNose Stock Up 6.6 %

OptiNose stock traded up $0.35 during midday trading on Tuesday, hitting $5.62. 51,128 shares of the stock were exchanged, compared to its average volume of 54,008. OptiNose, Inc. has a 52-week low of $4.82 and a 52-week high of $31.50. The business’s 50-day moving average price is $5.96 and its 200-day moving average price is $8.93. The stock has a market capitalization of $56.54 million, a price-to-earnings ratio of -1.34 and a beta of -0.17.

Analyst Ratings Changes

A number of equities analysts have issued reports on OPTN shares. HC Wainwright lifted their price target on OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Lake Street Capital cut their target price on OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. Finally, Piper Sandler lowered their price target on OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th.

Hedge Funds Weigh In On OptiNose

Several hedge funds have recently modified their holdings of the company. State Street Corp increased its position in shares of OptiNose by 14.2% during the third quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares during the last quarter. GSA Capital Partners LLP bought a new position in OptiNose in the 3rd quarter valued at $61,000. Easterly Investment Partners LLC increased its position in shares of OptiNose by 5.0% during the 3rd quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock valued at $1,581,000 after purchasing an additional 113,015 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of OptiNose by 5.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock worth $2,061,000 after purchasing an additional 155,329 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of OptiNose by 33.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock worth $870,000 after buying an additional 326,918 shares during the last quarter. Institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.